Humatrope


Also found in: Dictionary, Wikipedia.
Related to Humatrope: Norditropin, Genotropin

somatropin, recombinant

Genotropin, Humatrope, Norditropin, Nutropin AQ, Nutropin AQ Pen, Nutropin Depot, Omnitrope, Saizen, Serostim, Tev-Tropin, Zomacton (UK), Zorbtive

Pharmacologic class: Posterior pituitary hormone

Therapeutic class: Growth hormone (GH)

Pregnancy risk category B (Genotropin, Saizen, Serostim), C

Pregnancy risk category B (Genotropin, Saizen, Serostim), C

Action

Stimulates linear and skeletal growth, increases number and size of muscle cells, and influences internal organ size

Availability

Genotropin injection: 1.5 mg (about 4 international units/vial), 5.8 mg (about 15 international units/vial), 13.8 mg (about 41.4 international units/vial)

Humatrope injection: 2 mg (about 6 international units/vial), 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial), 12 mg (about 36 international units/vial), 24 mg (about 72 international units/vial)

Norditropin injection: 4 mg (12 international units/vial), 8 mg (24 international units/vial)

Norditropin injection cartridge: 5 mg/1.5 ml, 10 mg/1.5 ml, 15 mg/1.5 ml

Nutropin AQ injection: 10 mg

Nutropin AQ Pen injection cartridge: 10 mg

Nutropin Depot: 13.5-mg, 18-mg, and 22.5-mg single-use vials; 13.5-mg, 18-mg, and 22.5-mg kits

Nutropin injection: 5 mg (about 15 international units/vial), 10 mg (about 30 international units/vial)

Saizem injection: 5 g (about 15 international units/vial)

Serostim injection: 5 mg (about 15 international units/vial), 6 mg (about 18 international units/vial)

Tev-Tropin injection: 5 mg

Zorbtive injection: 8.8 mg in 10-ml vial

Indications and dosages

Growth failure in children with inadequate endogenous GH

Children: 0.16 to 0.24 mg/kg (Genotropin) subcutaneously q week in six or seven divided doses. Or 0.18 mg/kg/week (Humatrope) subcutaneously or I.M., divided equally and given on three alternate days six times weekly (or daily, if epiphyseal closure hasn't occurred). Or 0.024 to 0.034 mg/kg (Norditropin) subcutaneously six or seven times each week using NordiPen injection pen. Or 0.3 mg/kg/week (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously in equally divided daily doses. Or 0.06 mg/kg (Saizen) subcutaneously or I.M. three times weekly.

Endogenous GH replacement in adults with GH deficiency

Adults: 0.04 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses. Or 0.006 mg/kg/day (Humatrope) subcutaneously. Or initially, no more than 0.006 mg/kg/day (Nutropin AQ, Nutropin AQ Pen, Tev-Tropin) subcutaneously; may increase to a maximum of 0.025 mg/kg daily in patients younger than age 35 or 0.0125 mg/kg/day in patients ages 35 and older. Or 0.005 mg/kg/day (Saizen) subcutaneously; may increase to a maximum of 0.01 mg/kg/day after 4 weeks, depending on patient tolerance.

Short stature related to Turner's syndrome

Children: 0.375 mg/kg/week (Humatrope) subcutaneously, divided into equal doses given on 3 alternate days or daily. Or up to 0.375 mg/kg/week (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into equal doses given three or seven times weekly.

Idiopathic short stature (non-GH-deficient) in children whose epiphyses haven't closed

Children: Up to 0.37 mg/kg (Humatrope) subcutaneously q week. Divide dosage and give in equal doses six or seven times weekly.

Growth failure in children with Prader-Willi syndrome

Children: 0.24 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

Infants born small for gestational age

Children: 0.48 mg/kg/week (Genotropin) subcutaneously in six or seven divided doses

AIDS wasting or cachexia

Adults and children weighing more than 55 kg (121 lb): 6 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 45 to 55 kg (99 to 121 lb): 5 mg (Serostim) subcutaneously at bedtime

Adults and children weighing 35 to 45 kg (77 to 99 lb): 4 mg (Serostim) subcutaneously at bedtime

Adults and children weighing less than 35 kg (77 lb): 0.1 mg/kg/day (Serostim) subcutaneously at bedtime

Growth failure due to chronic renal insufficiency (up to time of kidney transplantation)

Children: Up to 0.35 mg/kg/weekly (Nutropin AQ, Nutropin AQ Pen) subcutaneously, divided into daily doses

Short bowel syndrome in patients receiving specialized nutritional support

Adults: 0.1 mg/kg/day subcutaneously (Zorbtive), to a maximum of 8 mg/day for no more than 4 weeks

Contraindications

• Hypersensitivity to drug, benzyl alcohol, glycerin, or metacresol (with some diluents)
• Active neoplasia
• Acute, critical illness after open-heart surgery, acute respiratory failure, or multiple trauma
• Children with closed epiphyses
• Neonates (Zorbtive)

Precautions

Use cautiously in:
• hypothyroidism
• diabetes mellitus.

Administration

• Reconstitute by injecting supplied diluent through rubber top of vial and aiming liquid stream at side of vial. Swirl vial gently to mix; don't shake.
• Inspect reconstituted solution. Don't use if it has visible particles or is cloudy.
• Keep diluted drug refrigerated; use within 14 days.
• When using prefilled cartridges, follow manufacturer's instructions carefully.
• Know that patients receiving Zorbtive for short bowel syndrome may receive specialized nutritional support as needed.

Adverse reactions

CNS: headache, weakness

CV: mild and transient edema

GU: hypercalciuria

Hematologic: leukemia

Metabolic: fluid retention, mild hyperglycemia, hypothyroidism, ketosis

Musculoskeletal: localized muscle pain, tissue swelling, joint pain

Skin: rash, urticaria

Other: pain, inflammation at injection site

Interactions

Drug-drug.Androgens, thyroid hormone: epiphyseal closure

Corticotrophin, corticosteroids: inhibited growth response (with long-term use)

Drug-diagnostic tests.Alkaline phosphatase, glucose, inorganic phosphorus, parathyroid hormone: increased levels

Patient monitoring

• Monitor patient's height, X-rays, blood chemistry results, blood glucose level, and thyroid function studies.

Watch for signs and symptoms of leukemia.

Patient teaching

• Advise patient and parents that regular check-ups and blood tests are needed to detect adverse reactions.
• Teach parents how to reconstitute and administer drug. Stress importance of following manufacturer's instructions carefully when using prefilled cartridges.
• Teach parents about proper handling and disposal of syringes, needles, and cartridges.
• As appropriate, review all significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

Humatrope

(ho͞o′mə-trōp′)
A trademark for a preparation of recombinant human growth hormone (somatropin).

Humatrope

a trademark for a brand of human synthetic growth hormone produced with recombinant deoxyribonucleic acid techniques. It is a polypeptide hormone with 191 amino acids in the same sequence as somatotropin, the human growth hormone produced by the pituitary gland.

Humatrope

Injectable rDNA somatropin Endocrinology A growth hormone for adult somatropin deficiency and short stature in girls with Turner syndrome. See Turner syndrome.

Humatrope

A brand name for SOMATOTROPIN.
References in periodicals archive ?
A time-and-motion simulation study found Norditropin pen devices took less total time weekly to use than the comparator Genotropin and Humatrope pen devices, due to differences in time to prepare the device and learn to use (Nickman, Haak, & Kim, 2010).
Now Humatrope is indicated for patients with severe adult growth hormone deficiency.
The company invested pounds 50m last year extending manufacturing capacity for Humatrope.
The major marketed products for GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin.
4% Genotropin, Humatrope, Disorders Norditropin, Nutropin, Omnitrope, Saizen, Tev-Tropin Sources: EMD Serono Specialty Digest, 7th edition, Express Scripts 2010 Drug Trend Report
The FDA approved a new indication for Humatrope, for long-term treatment of pediatric patients with idiopathic short stature, also known as non-growth hormone deficient short stature.
Last month Eli Lilly announced a pounds 28m investment in the Speke plant to increase capacity in the manufacture of Humatrope, which is used to treat growth hormone deficiency.
Speke, which employs 460 staff, is Lilly's leading manufacturer of Humatrope, used to treat growth hormone deficiency.
Paper presented at the meeting of the Tenth Annual Humatrope Symposium, Banff, Alberta, Canada.
Strong volume gains are also likely to come from ReoPro a leading therapeutic agent for preventing problems following angioplasty procedures: Gemzar anticancer agent: and such human insulin products as Humulin and Humatrope.
An advisory panel to the Food and Drug Administration recommended approval for an expanded indication of Humatrope to include treatment of non-growth hormone-deficient short stature.
The Speke Operations site, which has a 460-strong workforce, is Lilly's worldwide supplier of Humatrope, a biotech product used to treat growth hormone deficienc y.